Clinical trials: Recurrent IgA Nephropathy, open to volunteers
Immunoglobulin A Nephropathy, Kidney Diseases
A Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A Nephropathy
To determine the nephroprotective potential of treatment with sparsentan in (1: Cohort A) patients newly-diagnosed with immunoglobulin A nephropathy (IgAN) (ie, incident patients) who have not received prior…
- Conditions
- Immunoglobulin A Nephropathy, Kidney Diseases, Glomerulonephritis, IGA, Glomerulonephritis
- Trial name
- SPARTAN (NCT04663204)
- Testing
- Sparsentan
- Where
- 6 sites in United Kingdom
- Volunteers
- 24 people
- Sponsor
- University of Leicester